The Food and Drug Administration issued an approval for Novavax’s Covid-19 vaccine. This is the only non-mRNA vaccine.
The vaccine was approved for adults aged 65 and older and individuals aged 12 to 64 with at least one underlying health condition that increases their risk for severe COVID-19 outcomes. But reading the clinical trials prompts serious questions.
The trials included populations that had a single doses and populations that had two doses. The trials showed a reduction in symptomatic Covid 7 days after the second dose. But the FDA didn’t approve two doses. They only approved one. So is one dose even effective at all at preventing Covid? We don’t know, that wasn’t tested.
There is also a noted risk of myocarditis and heart inflammation but it is lower than that of mRNA Covid vaccines by Pfizer and Moderna. There was also at least one vaccine recipient with “a serious event of Guillain Barré syndrome reported 9 days following administration of” the vaccine. The FDA notes that Novavax has to follow up on any further cases if they observe it.
The FDA is also supposed to follow up on how the vaccine does when it is shipped to patients. They don’t know!? They don’t. They must submit a study called “Shipping Evaluation of SARS-CoV-2 rS (JN.1 Vaccine) Drug Product in Pre-Filled Syringe (PFS) Finished Good Presentation” by July of this year. This is not an uncommon practice at the FDA. They approve vaccines not knowing how they will fare once they are shipped to doctor’s offices. They test it on us.
Why would someone chose to take this given that its dosage was not trialed and its effectiveness unknown? Especially given the low prevalence of Covid. Your guess is as good as mine.
